ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PTK7 Antibody-drug Conjugate SKB518

Also written as “SKB518 for injection” and “SKB518”.

Its studies are mostly in Lung Neoplasms, led by Sichuan Kelun Pharmaceutical.

Drug pageAnti-PTK7 Antibody-drug Conjugate SKB518: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jun 5, 20253 company-led studies, 3 open or runningNext primary completion: Feb 20, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Kelun Pharmaceutical33 open or runningphase 2since Jun 5, 2025May 20, 2024Feb 20, 2027phase 2 · NCT07019675

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2024First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06428331 · 150 planned · China
  2. Jun 5, 2025Phase 2 study in Lung NeoplasmsNCT07019675 · 192 planned · China
  3. Feb 27, 2026Phase 2 study in Advanced Gynecological MalignanciesNCT07448922 · 280 planned · China

Ahead

  1. Feb 20, 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07019675
  2. Dec 31, 2027Primary completion: phase 2 study in Advanced Gynecological MalignanciesNCT07448922

TargetBeta

PTK7 →read by rule
“An antibody-drug conjugate (ADC) composed of an antibody directed against human inactive tyrosine-protein kinase 7 (protein tyrosine kinase 7; PTK7) ”NCIt, by rule

Other programs on PTK7

ProgramCompanyFurthest phaseStudies
Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301ruleday-one-biopharmaceuticals-incphase 11
Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408ruleEli Lillyphase 11
Anti-PTK7 Antibody-drug Conjugate HWK-007rulewhitehawk-therapeutics-incphase 11
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07448922Advanced Gynecological Malignancies · China2RecruitingDec 31, 2027280
NCT07019675Lung Neoplasms · China2RecruitingFeb 20, 2027192
NCT06428331Advanced Solid Tumors · China1RecruitingJun 30, 2026150

How it is read

Names in the registry

  • “SKB518 for injection”, 3 entries
  • “SKB518”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.